FISH Probes

BLADDER

Amplification at the 5p152.2 locus is strongly linked to high-grade, advanced-stage bladder tumors and rapid tumor cell proliferation in urinary cancer. Cytogenic analysis is demonstrated that 5p might be involved in translocations and/or formation of isochromosomes in a substancial number of bladder tumors. Gains at Chromosomes 3, 7, and 10 are seen more frequently in urothelial tumors.

Probe Name Target Colours Catalog Number
5p15.2 Red 5p15.2 CFA 7251 A
Copy Control 10 Green Copy Control 10 CFA 7200 A
Copy Control 3 Aqua Copy Control 3 CFA 7164 A
Copy Control 7 Orange Copy Control 7 CFA 7187 A

BREAST

Amplification of HER-2 has been demonstrated to predict poor clinical outcome in breast cancer patients, and is shown to be associated with resistance to certain chemotherapeutic agents. Determining amplification of HER-2 is crucial in the guidance of treatment decisions for the use of HER-2-targeted therapies, and is becoming a standard recommendation in the pretreatment work-up of patients with invasive breast cancer. Loss of PTEN may have prognostic significance in breast cancer, and was shown to be associated with poor clinical outcome in HER-2 positive disease.

Probe Name Target Colours Catalog Number
ERBB2 (17q12) Orange ERBB2 (HER-2) PFA 7273 V
ERBB2 (17q12) Red ERBB2 (HER-2) PFA 7274 V
ERBB2 (17q12) Orange + Copy Control 17 Green ERBB2 (HER-2) CFA 7164 A
ERBB2 (17q12) Red + Copy Control 17 Green ERBB2 (HER-2) PFR 7015 A
PTEN del-TECT™ Four Colour PTEN PFR 7032 A

CERVICAL

Amplification of TERC appears to be an important associated genetic event in the progression of cervical dysplasia to invasive cancer. 5p15.2 is another locus which displays significant amplification in association with progression to aggressive disease. Increases in genes at and near 20q13 have been specifically associated with cervical cancer progression to higher grade lesions.

Probe Name Target Colours Catalog Number
TERC (3q26.2) Red TERC (3q26) PFA 7305 V
5p15.2 Green 5p15.2 PFA 7250 V
5p15.2 Red 5p15.2 PFA 7251 V
20q13.2 Orange 20q13 (ZNF217) PFA 7255 V
TERC (3q26.2) Red/ 5p15.2 Green/ 20q13.2 Orange/ CC 10 Aqua 3q26/5p15.2/20q13/CC10 PFR 7043 A

GASTRIC/ESOPHAGEAL

The set of FISH probes consisting of MYC, CDKN2A (9p21), ERBB2 (HER-2), and 20q13.2 can provide high sensitivity and specificity for the detection of Barrett’s associated neoplasia and allow for the differentiation between esophageal adenocarcinoma and high-grade dysplasia (EAC/HGD) or low-grade dysplasia and non-dysplasia (LGD/ND).

Probe Name Target Colours Catalog Number
CDKN2A (p16) Orange CDKN2A PFA 7264 V
CDKN2A (9p21.3) Orange + Copy Control 9 Green CDKN2A PFR 7008 A
CDKN2A del-TECT™ Four Colour CDKN2A PFR 7007 A
MYC (8q24) Orange MYC PFA 7293 V
MYC (8q24) Orange + Copy Control 8 Green MYC PFR 7027 A
MYC (8q24) Break Apart (Orange/Green) MYC PFR 7026 A
ERBB2 (17q12) Orange ERBB2 (HER-2) PFA 7273 V
ERBB2 (17q12) Red ERBB2 (HER-2) PFA 7274 V
ERBB2 (17q12) Orange + Copy Control 17 Green ERBB2 (HER-2) PFR 7014 A
ERBB2 (17q12) Red + Copy Control 17 Green ERBB2 (HER-2) PFR 7015 A
20q13.2 Orange 20q13 (ZNF217) PFA 7255 V

LEUKAEMIA

Products for Chronic Lymphocytic Leukaemia Intended Use Volume (mL) Colours Catalog Number
D13S25 (13q14.3) Orange ASR 0.1 HFA 7266 A
D13S319 (13q14.2) Orange ASR 0.1 HFA 7267 A
RB1 (13q14.2) Orange ASR 0.1 HFA 7298 A
RB1 (13q14.2) Green ASR 0.1 HFA 7315 A
LAMP1 (13q34) Green ASR 0.1 HFA 7281 A
LAMP1 (13q34) Aqua ASR 0.1 HFA 7282 A
Copy Control 12 Green ASR 0.1 HFA 7210 A
Copy Control 12 Aqua ASR 0.1 HFA 7211 A
ATM (11q22.3) Orange ASR 0.1 HFA 7262 A
TP53 (17p13) Orange ASR 0.1 HFA 7306 A
IGH (14q32) Constant Orange ASR 0.1 HFA 7278 A
IGH (14q32) Variable Green ASR 0.1 HFA 7279 A
CCND1 (11q13) Orange ASR 0.1 HFA 7260 A
MYB (6q23) Orange ASR 0.1 HFA 7283 A
6q21 Green ASR 0.1 HFA 7309 A

LUNG

Recently, the ALK-EML4 fusion gene has been shown to be an important biomarker for ALK tyrosine kinase inhibitor (crizotinib) treatment in NSCLC, and Biocare’s unique ALK-EML4 Tri-Color allows detection of ALK break-apart and EML4 fusion in the same test. Patients with either ROS1 rearrangement or MET amplification have also been shown to respond to crizotinib treatment. Other small molecule kinase inhibitors have shown activity against RET break apart mutants.

Probe Name Target Colours Catalog Number
ALK/EML4 Tri-Colour ALK/EML4 PFR 7000 A
ALK/EML del-TECT™ Four Colour ALK/EML4 PFR 7001 A
ALK (2p23.2) Break Apart (Orange/Green) ALK (BA) PFR 7002 A
ALK (2p23.2) Break Apart (Red/Green) ALK (BA) PFR 7003 A
ROS1 (6q22) Break Apart (Orange/Green) ROS1 PFR 7038 A
RET (10q11.21) Break Apart (Orange/Green) RET PFR 7039 A
MET (7q31) Orange + Copy Control 7 Green MET PFR 7028 A

MELANOMA

Cytogenetic abnormalities in RREB1, MYB, and CCND1 loci detected by FISH are sensitive and specific markers of malignancy valuable for differentiating between benign and malignant melanocytic lesions. CDKN2A is frequently deleted in melanoma of all primary subtypes, and loss of both CDKN2A and CCND1 correlate with poor responses to inhibitor therapy.

Probe Name Target Colours Catalog Number
RREB1 (6p25) Orange RREB1 PFA 7299 V
RREB1 (6p25) Orange + Copy Control 6q11.1 Green RREB1 PFR 7037 A
Copy Control 6q11.1 Green Copy Control 6 PFA 7178 V
Copy Control 6q11.1 Aqua Copy Control 6 PFA 7179 V
MYB (6q23) Red/ 6q21 Green MYB PFR 7025 A
CCND1 (11q13) Orange CCND1 PFA 7260 V
CCND1 (11q13) Orange + Copy Control 11 Green CCND1 PFR 7006 A
CDKN2A (p16) Orange CDKN2A PFA 7264 V
CDKN2A (9p21.3) Orange + Copy Control 9 Green CDKN2A PFR 7008 A
CDKN2A del-TECT™ Four Colour CDKN2A PFR 7007 A

MYELOMA

Products for Chronic Multiple Myeloma Intended Use Volume (mL) Colours Catalog Number
CCND (11q13) Orange ASR 0.1 HFA 7260 A
FGFR3 (4q16.3) Aqua ASR 0.1 HFA 7276 A
FGFR3 (4q16.3) Orange ASR 0.1 HFA 7277 A
D13S25 (13q14.3) Orange ASR 0.1 HFA 7266 A
D13S319 (13q14.2) Orange ASR 0.1 HFA 7267 A
RB1 (13q14.2) Orange ASR 0.1 HFA 7298 A
RB1 (13q14.2) Green ASR 0.1 HFA 7315 A
LAMP1 (13q34) Green ASR 0.1 HFA 7281 A
LAMP1 (13q34) Aqua ASR 0.1 HFA 7282 A
TP53 (17q13) Orange ASR 0.1 HFA 7306 A
Copy Control 17 Green ASR 0.1 HFA 7225 A
1p21.2 Green ASR 0.1 HFA 7307 A
1q21.3 Orange ASR 0.1 HFA 7308 A

PROSTATE

With disease panels like PTEN, TMPRSS2/ERG and Androgen Receptor (AR), more informative disease stratification is possible. MYC amplification and NKX31 allelic loss are significant predictors of prostate cancer progression and aggressiveness. The novel tumor suppressor PHLPP1 is deleted as frequently as PTEN in prostate cancer, and may represent a therapeutic target for suppressing oncogenic pathways.

Probe Name Target Colours Catalog Number
PTEN del-TECT™ Four Colour PTEN PFR 7032 A
ERG (21q22) Break Apart (Red/Green) ERG (BA) PFR 7011 A
TMPRSS2/ERG del-TECT™ Four Colour ERG (BA) PFR 7049 A
AR (Xq12) Red + Copy Control Xp11.21 Green AR PFR 7004 A
NKX/MYC del-TECT™ Four Colour NKX3.1 PFR 7030 A
MYC (8q24) Orange MYC PFA 7293 V
MYC (8q24) Orange + Copy Control 8 Green MYC PFR 7027 A
MYC (8q24) Break Apart (Orange/Green) MYC PFR 7026 A
PHLPP1 (18q21) Red + Copy Control 18 Green PHLPP1 PFR 7035 A

To find out more about FISH Probes click here.

Contact Us